DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CANADIAN MULTICENTER TRIAL OF 2 DOSES OF SYNTHETIC SURFACTANT OR AIR PLACEBO IN 224 INFANTS WEIGHING 500 TO 749 GRAMS WITH RESPIRATORY-DISTRESS SYNDROME
J. Smyth et al., DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CANADIAN MULTICENTER TRIAL OF 2 DOSES OF SYNTHETIC SURFACTANT OR AIR PLACEBO IN 224 INFANTS WEIGHING 500 TO 749 GRAMS WITH RESPIRATORY-DISTRESS SYNDROME, The Journal of pediatrics, 126(5), 1995, pp. 81-89
In a multicenter, double-masked, placebo-controlled rescue trial condu
cted at 12 Canadian hospitals, two 5 ml/kg doses of a synthetic surfac
tant or air placebo were administered to 224 infants with birth weight
s of 500 to 749 gm who had established respiratory distress syndrome a
nd an arterial/alvealar oxygen tension ratio of less than 0.22. The fi
rst dose was given between 2 and 24 hours of age; the second dose was
given 12 hours later to the infants continuing to receive mechanical v
entilation. Infants were stratified at study entry by birth weight and
gender. Infants receiving synthetic surfactant showed significant imp
rovements in alveolar-arterial oxygen tension gradient, arterial/alveo
lar oxygen tension ratio, and oxygen and ventilator requirements throu
gh day 7. In the group randomized to synthetic surfactant, significant
improvements were seen in oxygen requirements at the first time point
measured (2 hours; p = 0.02), in the alveolar-arterial oxygen tension
gradient by the second time point measured (6 hours; p = 0.03), and i
n mean airway pressure after 6 hours. Overall mortality at 28 days was
not significantly different in the two groups (50% vs 46%, air placeb
o group vs synthetic surfactant group; p = 0.586). Similarly, neither
the incidence of bronchopulmonary dysplasia (37% vs 30%, air placebo g
roup vs synthetic surfactant group; p = 0.089) nor the incidence of su
rvival without BPD through 28 days (17% vs 26%, respectively; p = 0.07
0) was significantly different in the two groups. No significant diffe
rences in the incidence of safety-related outcomes or in adverse effec
ts such as apnea or pulmonary hemorrhage were noted. These findings in
dicate that rescue therapy with synthetic surfactant results in physio
logic improvements in very tiny premature infants, but improvements in
overall mortality or other complications of respiratory distress synd
rome were not documented in the sample evaluated.